Pivotal Study of the NanoKnife System for the Ablation of Prostate Tissue (PRESERVE)
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT04972097 |
|
Recruitment Status :
Recruiting
First Posted : July 22, 2021
Last Update Posted : March 24, 2023
|
Sponsor:
Angiodynamics, Inc.
Information provided by (Responsible Party):
Angiodynamics, Inc.
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Brief Summary:
Pivotal study to evaluate the use of the NanoKnife System as a focal therapy option for prostate cancer patients. This study will assess the safety and effectiveness of the device when used to ablate prostate tissue in intermediate-risk prostate cancer patients.
| Condition or disease | Intervention/treatment | Phase |
|---|---|---|
| Prostate Cancer | Device: Irreversible Electroporation | Not Applicable |
| Study Type : | Interventional (Clinical Trial) |
| Estimated Enrollment : | 118 participants |
| Allocation: | N/A |
| Intervention Model: | Single Group Assignment |
| Masking: | None (Open Label) |
| Primary Purpose: | Treatment |
| Official Title: | Pivotal Study of the NanoKnife System for the Ablation of Prostate Tissue in an Intermediate-Risk Patient Population |
| Actual Study Start Date : | March 29, 2022 |
| Estimated Primary Completion Date : | June 2024 |
| Estimated Study Completion Date : | June 2024 |
Resource links provided by the National Library of Medicine
MedlinePlus Genetics related topics:
Prostate cancer
MedlinePlus related topics:
Prostate Cancer
| Arm | Intervention/treatment |
|---|---|
|
Experimental: IRE Treatment Arm
All patients enrolled in this trial will receive IRE treatment with the NanoKnife System
|
Device: Irreversible Electroporation
IRE of the prostate is typically performed with the subject in the lithotomy position, with 2-6 monopolar probes placed through the perineum using a brachytherapy grid and ultrasound or CT guidance. IRE supplies the targeted tissue with high voltage (2-3 kV) direct current pulses lasting up to 100 microseconds through the electrode probes.
Other Name: The NanoKnife System |
Primary Outcome Measures :
- Rate of negative in-field biopsy at 12 months [ Time Frame: 12 months ]To determine the NanoKnife System's ablation effectiveness by measuring the negative in-field biopsy rate at 12 months
- Incidence of adverse events by type and CTCAE v5.0 severity through 12 months [ Time Frame: 12 months ]To determine the NanoKnife System's procedural and post-procedural safety profile by evaluation adverse event incidence, type, and severity through 12 months
Secondary Outcome Measures :
- Rate of negative in-field biopsy at 12 months as defined by the Delphi consensus criterion [ Time Frame: 12 months ]Rate of negative in-field biopsy at 12 months as defined by the Delphi consensus criterion of absence of clinically significant disease (≤ 3 mm of Gleason ≤ 6 disease in any biopsy core is insignificant)
- Assessment of urinary function by comparison of pre- and post-operative UCLA Expanded Prostate Cancer Index Composite [ Time Frame: 12 months ]Assessment of urinary function by comparison of pre- and post-operative UCLA Expanded Prostate Cancer Index Composite (UCLA-EPIC) Urinary Domain and International Prostate Symptom Scores (IPSS) and IPSS Quality of Life2 (IPSS-QoL) scores.
- Assessment of erectile function by comparison of pre- and post-operative IIEF-15 potency scores [ Time Frame: 12 months ]Assessment of erectile function by comparison of pre- and post-operative 15-Item International Index of Erectile Function (IIEF-15) potency scores.
- Effectiveness of therapy by measurement of prostate-specific antigen (PSA) kinetics [ Time Frame: 12 months ]Effectiveness of therapy by measurement of prostate-specific antigen (PSA) kinetics including time to PSA nadir.
- Assessment of changes in prostate volume [ Time Frame: 12 months ]Assessment of changes in prostate volume by comparison of pre-treatment and 12-month prostate volume measured via mpMRI.
- Assessment of ablation effectiveness by evaluation of prostate tissue by mpMRI [ Time Frame: 12 months ]Assessment of ablation effectiveness by evaluation of prostate tissue by mpMRI at 3 to 10 days post-treatment and at 12 months post-treatment.
- Assessment of need for secondary or adjuvant treatment [ Time Frame: 12 months ]Assessment of need for secondary or adjuvant treatment following treatment with the NanoKnife System.
- Evaluation of subject reported pre- and post-operative Quality of Life [ Time Frame: 12 months ]Evaluation of subject reported pre- and post-operative Quality of Life (QoL) using the 5-dimension scale EuroQol (EQ-5D®).
Information from the National Library of Medicine
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
| Ages Eligible for Study: | 50 Years and older (Adult, Older Adult) |
| Sexes Eligible for Study: | Male |
| Accepts Healthy Volunteers: | No |
Criteria
Inclusion Criteria:
- Is greater than 50 years of age
- Has at least a 10-year life expectancy
- Has histologically confirmed organ-confined prostate cancer, clinical stage ≤ T2c
- Has a PSA ≤ 15 ng/mL or PSA density < 0.2 ng/mL2 if PSA is > 15 ng/mL
- Has Gleason score 3+4 or 4+3
- Has no evidence of extraprostatic extension by mpMRI
- Has no evidence of seminal vesicle invasion by mpMRI, and if suspected, confirmed by biopsy
- Physician is able to visualize prostate gland adequately on transrectal ultrasound imaging during enrollment evaluation
- Transperineal or transrectal targeted prostate biopsies of lesion, plus 10 core systematic biopsies to include adequate sampling of the peripheral zone correlating with an intermediate risk lesion in the area of the MR-visible lesion
- A visible lesion on mpMRI that is accessible to Irreversible Electroporation (IRE) treatment (Note: A non-MRI visible lesion detected via systematic standard biopsy will not be considered an exclusion criterion provided the non-MRI visible lesion is singularly located in the contralateral hemisphere of the prostate; is Gleason 6; and comprises no more than 6 mm linear extent of prostate-bearing tissue in a single core on standard biopsy)
- Has signed a written informed consent and in the judgment of the physician, the study is in the best interest of the subject
- Understands and accepts the obligation and is logistically able to present for all scheduled follow-up visits
Exclusion Criteria:
- Has known hypersensitivity to pancuronium bromide, atricurium or cisatricurium
- Is unfit for anesthesia or has a contraindication for agents listed for paralysis
- Has an active urinary tract infection (UTI)
- Has a history of bladder neck contracture
- Is interested in future fertility
- Has a history (within 3 years) of inflammatory bowel disease
- Has a concurrent major debilitating illness
- Had active treatment for a malignancy within 3 years, including malignant melanoma, except for prostate cancer or other types of skin cancer
- Has any active implanted electronic device (e.g., pacemaker)
- Is unable to catheterize due to a urethral stricture disease
-
Has had prior or current prostate cancer therapies:
- Biologic therapy for prostate cancer
- Chemotherapy for prostate cancer
- Hormonal therapy for prostate cancer within three months of procedure
- Radiotherapy for prostate cancer
- Surgery for prostate cancer
- Has had prior transurethral prostatectomy (TURP), stricture surgery, urethral stent or prostatic implants
- Has had prior major rectal surgery (except hemorrhoids)
- Is unfit for pelvic MRI scanning (e.g., severe claustrophobia, permanent cardiac pacemaker, metallic implants that are likely to contribute significant image artifacts, allergy or contraindication to gadolinium (to enhance MRI))
- Is actively bleeding, is anticoagulated or on blood thinning medications, or has a bleeding disorder
- Is a member of a vulnerable population such as prisoners, handicapped or mentally disabled persons, or economically or educationally disadvantaged persons
- In the opinion of the treating physician, has a contraindication listed in the current NanoKnife System User Manual (section 2.3)
Information from the National Library of Medicine
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04972097
Contacts
| Contact: Elizabeth Manning | 339-237-2765 | liz.manning@angiodynamics.com |
Locations
Show 17 study locations
Sponsors and Collaborators
Angiodynamics, Inc.
Investigators
| Principal Investigator: | Jonathan Coleman, MD | Memorial Sloan Kettering Cancer Center | |
| Principal Investigator: | Arvin George, MD | University of Michigan |
| Responsible Party: | Angiodynamics, Inc. |
| ClinicalTrials.gov Identifier: | NCT04972097 |
| Other Study ID Numbers: |
2021-ONC-01 |
| First Posted: | July 22, 2021 Key Record Dates |
| Last Update Posted: | March 24, 2023 |
| Last Verified: | March 2023 |
| Individual Participant Data (IPD) Sharing Statement: | |
| Plan to Share IPD: | No |
| Studies a U.S. FDA-regulated Drug Product: | No |
| Studies a U.S. FDA-regulated Device Product: | Yes |
Keywords provided by Angiodynamics, Inc.:
|
Prostate Cancer Prostate Tissue NanoKnife System |
Focal Therapy Intermediate-Risk Irreversible Electroporation (IRE) |
Additional relevant MeSH terms:
|
Prostatic Neoplasms Genital Neoplasms, Male Urogenital Neoplasms |
Neoplasms by Site Neoplasms Prostatic Diseases |